No Interaction Expected
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Quality of Evidence:
Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Alogliptin is primarily excreted unchanged in the urine and undergoes negligible CYP-mediated metabolism. Furthermore, alogliptin was shown to be neither a substrate nor an inhibitor of the renal transporters OAT1, OAT3 or OCT2 and to cause no interactions with P-glycoprotein substrates.
View all available interactions with
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking